Browse the evidence

Overweight/obesity and physical inactivity are each responsible for nearly 1 in 10 deaths in the US, making them major contributors to preventable mortality.

Maintain a healthy weight and stay physically active. These two factors contribute to nearly 20% of all adult deaths combined. Addressing them through diet and exercise offers significant mortality benefits.

Macronutrient composition (low-carb vs. low-fat) has no significant difference on weight loss outcomes when total caloric intake and adherence are controlled.

Don't obsess over whether you should be low-carb or low-fat. The most important factor is that you eat fewer calories than you burn. You can achieve this with almost any dietary pattern (Mediterranean, low-carb, low-fat) as long as you stick to it and maintain a calorie deficit.

Liraglutide (3.0 mg daily) is effective for weight loss but significantly less so than Semaglutide, with a mean weight loss of 6.4% compared to 15.8%.

Liraglutide (3.0 mg daily) is an FDA-approved option for weight loss, but it produces roughly half the weight loss of Semaglutide (6.4% vs 15.8%). It requires daily injections, which may be burdensome, and you must reach the 3.0 mg dose to see full effects. If you cannot tolerate Semaglutide, this is a viable alternative, but expect less dramatic results.

Higher levels of systolic blood pressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI) are robustly associated with increased relative risks of cardiovascular diseases (CVD) and diabetes, with proportional effects declining as age increases.

Monitor your blood pressure, cholesterol, blood sugar, and weight regularly. The risk these factors pose to your heart and metabolic health is real and quantifiable. While the relative impact of each unit of risk decreases as you age, the absolute risk of events remains high, making management crucial at all adult ages. Prioritize keeping these metrics within healthy ranges through lifestyle and medical guidance as needed.

Sustained positive energy balance (energy intake exceeding energy expenditure) is the primary driver of obesity and weight gain.

To lose weight, you must consume fewer calories than you burn. While the quality of your diet (e.g., Mediterranean patterns, limiting sugary drinks) helps manage hunger and health, the fundamental requirement for weight loss is a sustained negative energy balance.

Certain anti-diabetic medications, specifically insulin, can increase body weight, creating a conflict in treating obesity and T2DM simultaneously.

If you are prescribed insulin for diabetes, be aware it can cause weight gain. Discuss weight-neutral or weight-loss promoting alternatives (like GLP-1 agonists or SGLT2 inhibitors, though not explicitly named here, implied by 'anti-obesity drugs') with your doctor if weight management is a priority.

Once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, physical limitations, and exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, independent of the magnitude of weight loss.

If you have heart failure with preserved ejection fraction, are obese, and have type 2 diabetes, once-weekly semaglutide (2.4 mg) can significantly reduce your heart failure symptoms and help you lose weight. This treatment works even if your weight loss isn't as dramatic as in people without diabetes, suggesting it helps your heart directly. It is administered as a weekly injection, starting at a low dose to minimize side effects, and titrated up over 16 weeks.

Replacing carbohydrates with Monounsaturated Fat (MUFA) lowers HbA1c and HOMA-IR, but does not significantly improve insulin secretion capacity (AIR) compared to PUFA.

Swapping carbohydrates for Monounsaturated Fats (like olive oil or avocados) can help lower HbA1c and improve insulin resistance. However, if your goal is to maximize insulin secretion capacity, Polyunsaturated Fats (PUFA) may offer an additional benefit that MUFA does not.

Intensive glycemic control fails to significantly improve cardiovascular outcomes in patients with diabetes, whereas cholesterol-lowering therapy significantly reduces cardiovascular events regardless of baseline lipid profiles.

If you have diabetes, managing your blood sugar is crucial for preventing kidney and eye damage, but it will not significantly protect your heart. To reduce your risk of heart attack or stroke, you must prioritize lowering your LDL cholesterol, even if your levels appear 'normal' on a standard test. Statin therapy is the most effective intervention for cardiovascular prevention in diabetes, regardless of your baseline lipid levels.

Statins are effective for primary and secondary prevention of cardiovascular disease in patients with diabetes, providing significant risk reduction even in patients with low baseline LDL cholesterol.

If you have diabetes, you should likely be on a statin, even if your cholesterol numbers look okay. Statins significantly reduce your risk of heart attack and stroke, and this benefit exists regardless of your baseline LDL. The small risk of developing diabetes from statins is far outweighed by the protection they offer your heart. Discuss high-intensity statins with your doctor if you are over 40 or have other risk factors.

Higher circulating levels of long-chain omega-3 fatty acids (EPA, DPA, DHA) are associated with a 15-18% lower risk of all-cause mortality compared to the lowest levels.

To potentially lower your risk of premature death, aim for higher blood levels of long-chain omega-3s (EPA, DHA, DPA). This study suggests that individuals with lower baseline levels may benefit most from increasing these fatty acids, potentially through supplementation if dietary intake is insufficient, as biomarker levels are a stronger predictor of longevity than self-reported fish consumption.

Higher circulating levels of long-chain omega-3 fatty acids are associated with lower risk of death from cardiovascular disease, cancer, and other causes.

Maintaining higher blood levels of marine omega-3s (EPA, DHA, DPA) is associated with a reduced risk of dying from heart disease, cancer, and other causes. This suggests that optimizing omega-3 status may support overall longevity beyond just heart health.

The thermic effect of food (TEF) varies significantly by nutrient type, with proteins inducing 20-30% energy expenditure, carbohydrates 5-10%, and fats 0-3%.

To maximize the energy cost of digestion, prioritize protein in your diet. Your body burns significantly more energy processing protein (20-30%) compared to fats (0-3%) or carbs (5-10%). This doesn't replace the need for a caloric deficit, but it adds a small metabolic advantage to higher-protein diets.

Group-based education excluding patients on insulin therapy results in greater reductions in HbA1c compared to interventions including patients on insulin therapy.

If you are on insulin, group education still helps, but the HbA1c reduction might be smaller than for those not on insulin. This may be due to the complexity of balancing insulin with lifestyle changes.

Training to muscle failure is not required for maximizing muscular strength or hypertrophy gains compared to training non-failure, provided training volume is equated.

You do not need to train to absolute muscular failure on every set to build maximum strength or muscle size. As long as you are close to failure (e.g., 1-3 reps in reserve) and you match the total number of reps/sets (volume) between your failure and non-failure groups, your results will be statistically identical. Prioritize non-failure training to reduce joint stress and improve recovery, unless you are a highly trained individual where failure might offer a slight hypertrophy edge.

The proportion of T2D attributable to diet is inversely correlated with age, being highest in younger adults (83.5% for ages 20-25) and lowest in older adults (27.7% for ages 95+).

Start eating well early in life. The proportion of diabetes cases driven by diet is highest in young adults, meaning early dietary habits have a massive impact on lifetime risk.

Genetically elevated body mass index (BMI) causally increases the risk of 316 distinct clinical diagnoses across circulatory, metabolic, respiratory, and genitourinary systems, with risk burden increasing significantly as BMI categories rise.

Your body weight is not just a cosmetic issue; it is a causal driver for hundreds of health conditions, including heart failure, diabetes, and sleep apnea. The risk increases as your BMI rises. Managing your weight through diet and activity is one of the most effective ways to reduce your risk for these specific, serious diseases, regardless of your genetic background.

GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.

GLP-1 medications slow down how fast food leaves your stomach. This helps you feel full longer and prevents sharp spikes in blood sugar after meals.

Endurance training increases absolute rates of fat oxidation but does not change the relative balance of substrate utilization (CHO vs. fat) when exercise is performed at the same relative intensity (percentage of VO2max).

Endurance training makes you faster and allows you to burn more fat in absolute terms, but your body still relies primarily on carbohydrates for energy at any given percentage of your maximum effort. Do not expect training alone to make you a 'fat-burning machine' at high intensities.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.

If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.

High body weight (obesity) causes increased psychological distress and depressive symptoms, primarily through weight stigma and biological mechanisms like HPA-axis dysregulation and systemic inflammation.

If you have obesity, be aware that societal stigma and biological factors like inflammation can contribute to depression. Focus on mental health support and reducing stigma rather than self-blame. Healthcare providers should adopt weight-inclusive attitudes to improve patient wellbeing.

Endurance-based exercise training induces skeletal muscle mitochondrial biogenesis through a hormetic feedback loop triggered by acute disruptions in cellular energy and ionic homeostasis.

To build more mitochondria and improve endurance, you must challenge your body's energy balance. This happens through endurance exercise (like running or cycling) or high-intensity interval training (HIIT). The key is that the exercise must be intense enough to disrupt your muscle's normal energy state (depleting ATP/creatine phosphate and raising AMP/Calcium), which signals your cells to build more mitochondria over time. Consistency and progressive overload are necessary because your body adapts to the stress.

Higher body mass index (BMI) is a strong, linear, and likely causal risk factor for severe COVID-19 outcomes, including hospitalization and death, with risk increasing by approximately 5-10% per kg/m² increase in BMI.

Maintaining a healthy weight is one of the most effective ways to reduce the risk of severe illness from COVID-19. The risk of hospitalization and death increases linearly with BMI. While weight loss is challenging, even modest reductions in weight (e.g., through bariatric surgery or lifestyle changes) have been associated with significantly lower risks of severe outcomes. Public health efforts should prioritize obesity prevention and management as a key strategy to mitigate the impact of the pandemic.

GLP-1 receptor agonists (GLP-1RAs) promote sustained weight loss in adults with obesity or type 2 diabetes primarily by increasing energy expenditure and reducing food intake via central nervous system satiety signaling, independent of glycaemic control.

If you have obesity or Type 2 Diabetes, GLP-1 medications like semaglutide or liraglutide are proven to help you lose significant weight (around 15% in trials) by reducing hunger and increasing energy burn. They are taken as a weekly or daily injection, often alongside diet and exercise changes. These are not quick fixes but chronic treatments that mimic a natural gut hormone to help regulate your body's weight set-point.